Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Michael Prisant

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Preventive Cardiology|May 30, 2009
Now or never: optimal antihypertensive therapy in the elderlyL Michael Prisant
American Journal of Therapeutics|September 17, 2003
Diabetes mellitus and hypertension: a mandate for intense treatment according to new guidelinesL Michael Prisant
Journal of Clinical Hypertension (Greenwich, Conn.)|October 8, 2004
Blunted nocturnal decline in blood pressureL Michael Prisant
Journal of Clinical Pharmacology|December 18, 2007
Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blockerL Michael Prisant
Journal of Clinical Hypertension (Greenwich, Conn.)|April 3, 2002
Transdermal clonidine skin reactionsL Michael Prisant
Managed Care (Langhorne, Pa.)|September 16, 2003
Fixed low-dose combination therapy: current recommendationsL Michael Prisant
Journal of Clinical Pharmacology|March 31, 2004
Diabetes mellitus: an imperative for prevention and intense managementL Michael Prisant
Postgraduate Medicine|August 12, 2009
Challenges for beta-blockers as first-line therapy for elderly hypertensive patientsL Michael Prisant
Journal of Clinical Hypertension (Greenwich, Conn.)|July 31, 2002
Should beta blockers be used in the treatment of hypertension in the elderly?L Michael Prisant
Journal of Clinical Pharmacology|March 31, 2004
Preventing type II diabetes mellitusL Michael Prisant
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Preventive Cardiology|May 30, 2009
Now or never: optimal antihypertensive therapy in the elderlyL Michael Prisant
American Journal of Therapeutics|September 17, 2003
Diabetes mellitus and hypertension: a mandate for intense treatment according to new guidelinesL Michael Prisant
Journal of Clinical Hypertension (Greenwich, Conn.)|October 8, 2004
Blunted nocturnal decline in blood pressureL Michael Prisant
Journal of Clinical Pharmacology|December 18, 2007
Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blockerL Michael Prisant
Journal of Clinical Hypertension (Greenwich, Conn.)|April 3, 2002
Transdermal clonidine skin reactionsL Michael Prisant
Managed Care (Langhorne, Pa.)|September 16, 2003
Fixed low-dose combination therapy: current recommendationsL Michael Prisant
Journal of Clinical Pharmacology|March 31, 2004
Diabetes mellitus: an imperative for prevention and intense managementL Michael Prisant
Postgraduate Medicine|August 12, 2009
Challenges for beta-blockers as first-line therapy for elderly hypertensive patientsL Michael Prisant
Journal of Clinical Hypertension (Greenwich, Conn.)|July 31, 2002
Should beta blockers be used in the treatment of hypertension in the elderly?L Michael Prisant
Journal of Clinical Pharmacology|March 31, 2004
Preventing type II diabetes mellitusL Michael Prisant
Pageof 6